Shunting a more frequent treatment than ONSF for pseudotumor cerebri syndrome: JAMA
USA: Shunting is used more frequently than optic nerve sheath fenestration (ONSF) for treatment of pseudotumor cerebri syndrome (PTCS), suggests a recent study in JAMA Network Open.The findings reflect underlying trends in medical treatment practices and outcomes or growing limitations in access to ophthalmic surgical expertise.Optic nerve sheath fenestration and cerebrospinal fluid shunting...
USA: Shunting is used more frequently than optic nerve sheath fenestration (ONSF) for treatment of pseudotumor cerebri syndrome (PTCS), suggests a recent study in JAMA Network Open.
The findings reflect underlying trends in medical treatment practices and outcomes or growing limitations in access to ophthalmic surgical expertise.
Optic nerve sheath fenestration and cerebrospinal fluid shunting are used sometimes for the treatment of pseudotumor cerebri syndrome but their use patterns are not known. To fill this knowledge gap, Ali G. Hamedani, University of Pennsylvania, Philadelphia, and colleagues aimed to investigate the frequency of surgical PTCS treatment in the United States and to compare patients undergoing ONSF with those treated with shunting.
For the purpose, the researchers set up a retrospective longitudinal cross-sectional study. They obtained inpatient data from the National Inpatient Sample (NIS), and outpatient surgical center data from the National Survey of Ambulatory Surgery (NSAS) and National Hospital Ambulatory Medical Care Survey (NHAMCS).
The analysis included 10 720 patients (18 to 65 years) with a diagnosis code for PTCS. Patients with venous thrombosis and intracranial hypertension were excluded. Time trends were explored and logistic regression was used to measure differences according to age, race/ethnicity, sex, Elixhauser comorbidity index, and other patient and hospital characteristics. Data analysis was performed from March 31 to October 7, 2020.
The outcomes included annual number of PTCS-related admissions, ONSFs, and shunt procedures from 2002-2016. Patient and hospital-level characteristics of patients with PTCS undergoing ONSF or shunting were compared.
Key findings of the study include:
- Between 2010 and 2016, 297 ONSFs were performed and 10 423 shunts were placed as treatment for PTCS.
- The procedures were most commonly performed in individuals aged 26 to 35 years (39.4%), and 9920 (92.4%) of the surgically treated patients were women.
- ONSF was more common among younger patients (eg, adjusted odds ratio [AOR] for patients ≥46 years vs those 18-25 years, 0.22) and in Black, Hispanic, or other minority populations (AOR, 2.37) and less common in the South (AOR, 0.34) and West (AOR, 0.15) compared with the Northeast.
- Total PTCS-related hospitalizations increased from 6081 in 2002 to 18 020 in 2016. Shunting increased from 2002 to 2011 and subsequently plateaued and declined.
- ONSF was used much less frequently, and use has not increased.
- No instances of outpatient ONSF or shunting for PTCS were recorded in the NSAS or NHAMCS databases.
"Findings from our study suggest that shunting is more common than ONSF and that the use gap has widened as shunting has increased. However, because overall PTCS-related hospitalizations have increased even more rapidly, the percentage of inpatients with PTCS undergoing surgery has decreased," wrote the authors.
"These trends may reflect changes in medical treatment practices and outcomes or growing limitations in access to ophthalmic surgical expertise," they concluded.
The study, "Trends in the Surgical Treatment of Pseudotumor Cerebri Syndrome in the United States," is published in the journal JAMA Network Open.
DOI: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774167
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd